GSK and Biological E Form Joint Venture to Develop Novel Six-in-One Pediatric Vaccine
Key Insights
GSK and Biological E (search) have established a 50/50 joint venture to develop a first-of-its-kind combination vaccine that would protect children against polio (search) and five other infectious diseases.
The innovative vaccine combines GSK's injectable polio (search) vaccine with Biological E (search)'s pentavalent vaccine, potentially reducing the number of required injections and improving immunization compliance.
The development costs will be shared equally between both companies, with phase 1 trials expected to begin within the next two years.
In a significant move to advance pediatric immunization in developing countries, GlaxoSmithKline (GSK) has partnered with Indian vaccine manufacturer Biological E (search) to develop an innovative six-in-one combination pediatric vaccine. The joint venture, structured as a 50/50 partnership, aims to create a groundbreaking vaccine that could revolutionize childhood immunization programs in India and other developing nations.
The proposed combination vaccine merges GSK's injectable polio (search) vaccine (IPV) with Biological E (search)'s established pentavalent vaccine, which currently protects against diphtheria (search), tetanus (search), whooping cough (search) (whole cell pertussis), hepatitis B (search), and Haemophilus influenzae type b (search). If successful, this would mark the first time these six antigens have been combined into a single vaccine.
Strategic Benefits and Clinical Impact
The development of this combination vaccine addresses several critical challenges in pediatric immunization. By reducing the number of required injections, the vaccine could significantly improve compliance with immunization schedules, a crucial factor in achieving better vaccination coverage in developing regions.
Christophe Weber, President of GSK Vaccines, emphasized the strategic importance of the partnership: "We are delighted to be working with Biological E (search), an established company in the global vaccine market. This agreement is fully aligned to GSK's vision of providing high quality vaccines to those in need and by leveraging Biological E's strengths, this particular vaccine has the potential to play a significant role in the fight against polio (search)."
Development Timeline and Financial Structure
The joint venture partners have outlined a clear development pathway for the candidate vaccine. Phase 1 clinical trials are expected to commence within the next two years, with both companies making initial cash investments to cover start-up costs. Subsequent development costs will be shared equally between GSK and Biological E (search).
Supporting Global Health Initiatives
This collaboration aligns with the World Health Organization's global polio (search) eradication program, demonstrating both companies' commitment to public health initiatives. The partnership combines GSK's global vaccine expertise with Biological E (search)'s strong presence in the Indian market and developing world.
The transaction is expected to be completed in 2013, subject to regulatory approvals and other standard closing conditions. This strategic alliance represents a significant step forward in simplifying childhood immunization programs while maintaining comprehensive protection against six major infectious diseases.